comparemela.com

Latest Breaking News On - Efficiency in health care - Page 1 : comparemela.com

Aflibercept in AMD: no proof of added benefit

Manufacturer's dossier did not contain any usable data for the comparison with ranibizumab The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG)…

vimarsana © 2020. All Rights Reserved.